An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present).

IF 5.4 2区医学 Q1 CHEMISTRY, MEDICINAL

Expert Opinion on Therapeutic Patents Pub Date : 2023-10-01 Epub Date: 2024-01-10 DOI:10.1080/13543776.2023.2284935

Suvankar Banerjee, Sandip Kumar Baidya, Nilanjan Adhikari, Tarun Jha

{"title":"An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present).","authors":"Suvankar Banerjee, Sandip Kumar Baidya, Nilanjan Adhikari, Tarun Jha","doi":"10.1080/13543776.2023.2284935","DOIUrl":null,"url":null,"abstract":"Introduction: Matrix metalloproteinases (MMPs) are strongly interlinked with the progression and mechanisms of several life-threatening diseases including cancer. Thus, novel MMP inhibitors (MMPIs) as promising drug candidates can be effective in combating these diseases. However, no MMPIs are marketed to date due to poor pharmacokinetics and lower selectivity. Therefore, this review was performed to study the newer MMPIs patented after the COVID-19 period for an updated perspective on MMPIs.Areas covered: This review highlights patents related to MMPIs, and their therapeutic implications published between January 2021 and August 2023 available in the Google Patents, Patentscope, and Espacenet databases.Expert opinion: Despite various MMP-related patents disclosed up to 2020, newer patent applications in the post-COVID-19 period decreased a lot. Besides major MMPs, other isoforms (i.e. MMP-3 and MMP-7) have gained attention recently for drug development. This may open up newer dimensions targeting these MMPs for therapeutic advancements. The isoform selectivity and bioavailability are major concerns for effective MMPI development. Thus, adopting theoretical approaches and experimental methodologies can unveil the development of novel MMPIs with improved pharmacokinetic profiles. Nevertheless, the involvement of MMPs in cancer, and the mechanisms of such MMPs in other diseases should be extensively studied for novel MMPI development.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"631-649"},"PeriodicalIF":5.4000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2023.2284935","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Matrix metalloproteinases (MMPs) are strongly interlinked with the progression and mechanisms of several life-threatening diseases including cancer. Thus, novel MMP inhibitors (MMPIs) as promising drug candidates can be effective in combating these diseases. However, no MMPIs are marketed to date due to poor pharmacokinetics and lower selectivity. Therefore, this review was performed to study the newer MMPIs patented after the COVID-19 period for an updated perspective on MMPIs.

Areas covered: This review highlights patents related to MMPIs, and their therapeutic implications published between January 2021 and August 2023 available in the Google Patents, Patentscope, and Espacenet databases.

Expert opinion: Despite various MMP-related patents disclosed up to 2020, newer patent applications in the post-COVID-19 period decreased a lot. Besides major MMPs, other isoforms (i.e. MMP-3 and MMP-7) have gained attention recently for drug development. This may open up newer dimensions targeting these MMPs for therapeutic advancements. The isoform selectivity and bioavailability are major concerns for effective MMPI development. Thus, adopting theoretical approaches and experimental methodologies can unveil the development of novel MMPIs with improved pharmacokinetic profiles. Nevertheless, the involvement of MMPs in cancer, and the mechanisms of such MMPs in other diseases should be extensively studied for novel MMPI development.

查看原文本刊更多论文

基质金属蛋白酶(MMP)抑制剂专利综述(2021年至今)

基质金属蛋白酶(MMPs)与包括癌症在内的几种危及生命的疾病的进展和机制密切相关。因此，新型MMP抑制剂(MMPIs)作为有希望的候选药物可以有效地对抗这些疾病。然而，由于药代动力学差和选择性较低，迄今为止还没有mmpi上市。因此，本综述旨在研究在COVID-19期间获得专利的新型mmpi，以获得对mmpi的最新看法。涵盖领域:本综述重点介绍了2021年1月至2023年8月期间发表的与MMPIs相关的专利及其治疗意义，这些专利可在谷歌patents、Patentscope和Espacenet数据库中获得。专家意见:尽管截至2020年，mmp相关专利已公开，但新专利申请在新冠肺炎疫情后大幅减少。除了主要的MMPs外，其他同工型(即MMP-3和MMP-7)最近也受到了药物开发的关注。这可能会为治疗进展开辟针对这些MMPs的新维度。同种异构体的选择性和生物利用度是有效开发MMPI的主要问题。因此，采用理论方法和实验方法可以揭示具有改进药代动力学特征的新型mmpi的开发。尽管如此，MMPs在癌症中的参与，以及这种MMPs在其他疾病中的机制，应该广泛研究新型MMPI的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Patents 医学-药学

CiteScore

12.10

自引率

1.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.